General practitioners and pediatricians must know the signs and
symptoms of possible pediatric cancer.
Ce document est consolidé par OCHA pour le compte de l’Équipe humanitaire pays et des partenaires humanitaires. Il présente une compréhension commune de la crise, notamment les besoins humanitaires les plus pressants et le nombre estimé de personnes ayant besoin d’assistance. Il constitue u...ne base factuelle aidant à informer la planification stratégique conjointe de la réponse.
Les désignations employées et la présentation des éléments dans le présent rapport ne signifient pas l’expression de quelque opinion que ce soit de la part du Secrétariat des Nations unies concernant le statut juridique d’un pays, d’un territoire, d’une ville ou d’une zone ou de leurs autorités ou concernant la délimitation de ses frontières ou de ses limites.
more
L’ampleur de la crise en 2021 s’est accentuée avec l’expansion de la violence et de l’insécurité dans tout le nord et le centre, et vers le sud du pays. Dans ce contexte de sous-investissements, de pauvreté chronique, de crise sociopolitique, les conflits, l’insécurité multiforme et ...les aléas climatiques (inondations et sécheresses) couplées aux conséquences socioéconomiques de la COVID-19, constituent les principaux déterminants de la crise humanitaire. La juxtaposition de ces aléas menace la vie, accentue les vulnérabilités préexistantes, fragilise les moyens d’existence des ménages affectés et amenuise leur capacité de résilience
more
Rapport d’étape au 30 novembre 2011
These Guidelines are intended to provide knowledge to the treating ophthalmologists, pediatricians, ocular oncologists, pediatric oncologists, and general physicians to arrive at an early diagnosis of retinoblastoma in the settings of district hospital, in private clinics and hospitals. The guidelin...es will enable the contact health personnel to refer at the right
time to the tertiary care hospital for management of retinoblastoma.
more
The cardiovascular disease continuum begins with risk factors such as diabetes mellitus (DM), progresses to vasculopathy and myocardial dysfunction, and finally ends with cardiovascular death. Diabetes is associated with a 2- to 4-fold increased risk for heart failure (HF). Moreover, HF patients wit...h DM have a worse prognosis than those without DM. Diabetes can cause myocardial ischemia via micro- and macrovasculopathy and can directly exert deleterious effects on the myocardium. Hyperglycemia, hyperinsulinemia, and insulin resistance can cause alterations in vascular homeostasis. Then, reduced nitric oxide and increased reactive oxygen species levels favor inflammation leading to atherothrombotic progression and myocardial dysfunction. The classification, diagnosis, and treatment of HF for a patient with and without DM remain the same. Until now, drugs targeting neurohumoral and metabolic pathways improved mortality and morbidity in HF with reduced ejection fraction (HFrEF). Therefore, all HFrEF patients should receive guideline-directed medical therapy. By contrast, drugs modulating neurohumoral activity did not improve survival in HF with preserved ejection fraction (HFpEF) patients. Trials investigating whether sodium-glucose cotransporter-2 inhibitors are effective in HFpEF are on-going. This review will summarize the epidemiology, pathophysiology, and treatment of HF in diabetes.
more
• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States;
• provide models to assist Member States in developing their own mono- graphs or formularies for these... or other herbal medicines; and
• facilitate information exchange among Member States.
more
Report of the 23rd WHO Expert Committee on the selection and use of essential medicines
This executive summary reports the recommendations made by the Expert Committee for the 2021 update of the WHO Model List of Essential Medicines (EML) and the Model List of Essential Medicine for Children (EMLc)....
The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and formulation on the Model Lists of Essential Medicines. The Committee evaluated the scientific evidence for comparative effectiveness, safety and cost-effectiveness of the medicines in question. The Committee also considered a review of the therapeutic alternatives for medicines on the Model Lists, and update to the AWaRe classification of antibiotics, and reviews and reports relevant to the selection and use of essential medicines.
more
Jin et al. Military Medical Research (2020) 7:4 https://doi.org/10.1186/s40779-020-0233-6
Position Article und Guideline